Avinger INC 8-K filings

Avinger, Inc. has entered into a general assignment for the benefit of creditors, resulting in the termination of key executives and resignations of board members.

Avinger, Inc. stockholders have approved a proposal for assignment for the benefit of creditors followed by a voluntary dissolution and liquidation, contingent on the board's assessment of the best interests of the company and its stockholders.

Avinger Inc.'s special stockholder meeting was adjourned due to a lack of quorum and will reconvene on February 5, 2025.

Avinger, Inc. is shifting its focus from peripheral artery disease (PAD) to coronary artery disease (CAD) treatment, resulting in the termination of 36 employees and the cessation of PAD product manufacturing.

Avinger, Inc. declared and paid dividends in the form of preferred stock and increased the designated number of Series F preferred shares.

Avinger Inc. held its 2024 Annual Meeting where stockholders approved an amended equity incentive plan, elected directors, and ratified the appointment of an independent accounting firm.

Avinger Inc.'s top executives have waived their rights to change of control and severance benefits as the company prepares for a potential assignment for the benefit of creditors followed by a voluntary dissolution and liquidation.

Avinger Inc. has defaulted on its loan agreement and is proposing an assignment for the benefit of creditors followed by a voluntary dissolution and liquidation.

Avinger, Inc. has been notified by Nasdaq that it is not in compliance with listing rules due to its stock price falling below $1 for an extended period.

Avinger, Inc. announced improved financial results for the third quarter of 2024, driven by cost reductions and increased gross margins, while also progressing its coronary product development.

Avinger, Inc. has increased the amount available for sale under its At-the-Market Offering Agreement by an additional $1,324,918 to raise capital for working capital and general corporate purposes.

Avinger Inc. stockholders approved the issuance of shares upon exercise of warrants and the adjournment of the special meeting if required.

Avinger announced its second quarter 2024 financial results, highlighted by a revenue of $1.8 million, a 20% gross margin, and progress in its coronary product line development.

Avinger, Inc. has successfully priced a public offering, raising an initial $6 million with the potential for an additional $18 million through the exercise of milestone-linked warrants.

Avinger, Inc. has amended its term loan agreement to temporarily reduce the minimum liquidity covenant from $3.5 million to $1.5 million for a two-month period.

Avinger, Inc. has regained compliance with Nasdaq's stockholders' equity requirement, closing a listing matter and avoiding delisting.

Avinger, Inc. stockholders approved the issuance of common stock upon conversion of Series F and G Preferred Stock at a special meeting on May 22, 2024.

Avinger, Inc. has converted $11 million of its debt with CRG Partners III L.P. into a new series of convertible preferred stock, significantly improving its balance sheet.

Avinger, Inc. announced its first quarter 2024 financial results, reporting flat revenue year-over-year, while highlighting progress in coronary product development and a new strategic partnership.

Avinger announced a strategic partnership with Zylox-Tonbridge, securing $15 million in funding, while reporting a 5% sequential revenue increase for Q4 2023 and advancing its coronary product development.

Avinger, Inc. has extended its headquarters lease in Redwood City, California for an additional year, securing the facility through November 2025.

Avinger has entered into a strategic partnership with Zylox-Tonbridge, including a $15 million investment, to expand its product distribution and manufacturing into the Greater China region.

Avinger, Inc. has entered into a strategic partnership with Zylox-Tonbridge, including up to $15 million in equity funding, a licensing agreement for the Greater China market, and a technology transfer agreement.

Avinger, Inc. has amended its term loan agreement, temporarily reducing its minimum liquidity requirement to $1 million until April 1, 2024.